Y Intercept Hong Kong Ltd Sells 791,446 Shares of Sarepta Therapeutics, Inc. $SRPT

Y Intercept Hong Kong Ltd decreased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 91.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 78,735 shares of the biotechnology company’s stock after selling 791,446 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Sarepta Therapeutics were worth $1,517,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Byrne Asset Management LLC bought a new position in Sarepta Therapeutics during the 3rd quarter valued at approximately $33,000. Covestor Ltd grew its stake in shares of Sarepta Therapeutics by 1,081.8% in the third quarter. Covestor Ltd now owns 2,789 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 2,553 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Sarepta Therapeutics by 542.3% during the second quarter. Blue Trust Inc. now owns 3,282 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 2,771 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Sarepta Therapeutics by 285.6% during the third quarter. GAMMA Investing LLC now owns 3,089 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 2,288 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of Sarepta Therapeutics by 61.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,779 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 1,444 shares during the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Sarepta Therapeutics

In related news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the transaction, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at approximately $4,312,523. This represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.60% of the company’s stock.

Sarepta Therapeutics Trading Down 4.2%

Shares of NASDAQ:SRPT opened at $20.34 on Friday. Sarepta Therapeutics, Inc. has a 12-month low of $10.41 and a 12-month high of $120.05. The company has a market cap of $2.13 billion, a PE ratio of -6.76, a price-to-earnings-growth ratio of 0.52 and a beta of 0.48. The stock has a 50 day moving average of $21.56 and a 200 day moving average of $19.89. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.15). The firm had revenue of $399.36 million during the quarter, compared to the consensus estimate of $331.51 million. Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The company’s quarterly revenue was down 14.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.62 EPS. As a group, equities research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analyst Upgrades and Downgrades

SRPT has been the subject of several recent analyst reports. Piper Sandler lifted their target price on shares of Sarepta Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, October 30th. Bank of America raised their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company an “underperform” rating in a research report on Wednesday, October 22nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Robert W. Baird reduced their target price on Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. Finally, HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a report on Tuesday. Nine research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $33.84.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.